Phaseline

Companies › medac

medac: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Immunology; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MC0518
Mesenchymal stromal cells
–Phase 3Steroid-refractory Acute Graft-versus-host DiseaseAug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04629833MC0518Phase 3Steroid-refractory Acute Graft-versus-host DiseaseImmunologyAug 2027
NCT06075706MC0518Phase 2Steroid-refractory Acute Graft-versus-host DiseaseImmunologyJun 2031

From the company's SEC filings

Complete response letters from FDA

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Doron Therapeutics UnicoCell Biomed ALK-Abelló Kolon TissueGene Inmunotek

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.